“…However, Sativex is not yet approved by the US FDA, with the agency indicating that there may be associated health risks, as there is limited research regarding its safety. Confusion, ideomotor slowing, fatigue, nausea and dizziness in MS patients, and nausea, vomiting, somnolence and dizziness in cancer patients are reported as some of the most prevalent side effects of Sativex [40,41]. The discovery of biological targets that are modulated by cannabis-derived components such as G protein-coupled receptors (GPCRs), including cannabinoid receptor 1 (CB1R), cannabinoid receptor 2 (CB2R), ion channels, and various nuclear receptors, has increased our understanding of how cannabis interacts with the human body [42][43][44].…”